Microglial Nr4a1 and Neuronal C3: Mechanisms Linking TMJ Inflammation to Hippocampal Synaptic Loss and Depression

Study Background and Research Question

Temporomandibular disorders (TMD) affect millions globally, often manifesting as chronic orofacial pain and functional impairment. Beyond these physical symptoms, patients with TMD are at increased risk for depression and anxiety, compounding the disease burden. While the association between inflammation in the temporomandibular joint (TMJ) and emotional disorders is well recognized, the molecular and cellular mechanisms by which TMJ inflammation influences central nervous system (CNS) function have remained largely elusive. Specifically, the hippocampus—a region critical for mood regulation—shows altered connectivity and neuroinflammation in depression, but the pathways connecting peripheral joint inflammation to hippocampal synaptic remodeling have not been fully delineated.

Key Innovation from the Reference Study

The reference study (Zhu et al., 2026) provides a mechanistic breakthrough by demonstrating that TMJ inflammation induces hippocampal microglial activation and abnormal synaptic pruning, mediated by nuclear receptor subfamily 4 group A member 1 (Nr4a1) deficiency and neuronal complement 3 (C3) upregulation. This dual mechanism leads to excessive synapse loss and depression-like behaviors in mice, establishing a direct link between peripheral inflammation and central synaptic pathology.

Methods and Experimental Design Insights

The investigators used a robust mouse model of TMJ inflammation, induced by intra-articular injection of complete Freund’s adjuvant (CFA). Behavioral assays assessed depression-like phenotypes, while immunohistochemistry and immunofluorescence were employed to quantify microglial activation, synaptic markers, and the deposition of C3 in the hippocampus (HPC). Genetic manipulations included conditional silencing and overexpression of Nr4a1 in microglia, as well as manipulation of C3 levels in neurons. Pharmacological suppression of microglial activity was achieved with minocycline. The study integrated molecular, cellular, and behavioral endpoints to delineate the sequence of events from TMJ inflammation to hippocampal dysfunction.

Core Findings and Why They Matter

Following CFA-induced TMJ inflammation, mice exhibited pronounced depression-like behaviors, including reduced sucrose preference and increased immobility in forced swim tests. Concurrently, hippocampal microglia showed increased activation and phagocytic activity, with evidence of excessive synaptic pruning as indicated by loss of synaptic markers. The critical findings are as follows:

• Microglial Nr4a1 downregulation: TMJ inflammation led to a significant reduction in Nr4a1 expression in hippocampal microglia. Genetic silencing of Nr4a1 further promoted microglial activation, upregulation of lysosomal marker CD68, and enhanced synaptic engulfment.
• NF-κB signaling involvement: Mechanistically, Nr4a1 deficiency in microglia was linked to activation of the NF-κB pathway, suggesting that inflammatory transcriptional reprogramming is central to aberrant phagocytic activity.
• Neuronal C3 upregulation: Complement 3 (C3), a classical tag for synaptic pruning, was markedly upregulated in hippocampal neurons after TMJ inflammation. Immunofluorescence confirmed colocalization of C3 with synaptic terminals and microglia, correlating with synaptic loss.
• Functional consequences: Overexpression of C3 in neurons alone was sufficient to drive excessive synaptic pruning and induce depression-like behaviors, underscoring its sufficiency as a pathological mediator.
• Therapeutic implication: Suppressing microglial activation with minocycline or restoring Nr4a1 expression ameliorated both synaptic pathology and behavioral deficits, positioning these molecular nodes as potential therapeutic targets.

Together, these results provide compelling evidence that TMJ inflammation triggers a cascade—via microglial Nr4a1 deficiency and neuronal C3 upregulation—culminating in aberrant synaptic remodeling and mood dysregulation. The study not only elucidates the molecular underpinnings of TMD-associated emotional comorbidities but also identifies actionable targets within the microglia–neuron axis.

Comparison with Existing Internal Articles

Several internal resources expand on the role of PKC/NF-κB signaling in neuroinflammation and osteoclastogenesis. For example, "Verbascoside: PKC/NF-κB Inhibitor for Osteoclastogenesis" and "Verbascoside: Precision PKC/NF-κB Inhibition for Cell Signaling" detail how PKC/NF-κB pathway inhibitors, such as Verbascoside, can modulate inflammatory responses and cell fate in both bone and neural models. The reference study’s demonstration that NF-κB activation is downstream of Nr4a1 deficiency in microglia supports the rationale for using PKC/NF-κB inhibitors in CNS inflammation models. Moreover, the use of RANKL-treated RAW264.7 cells and bone marrow macrophages for assessing PKC/NF-κB inhibition in osteoclastogenesis research, as described in these internal articles, parallels the methodologies for dissecting microglial activation and signaling in neuroinflammation. Thus, the present findings bridge the gap between peripheral immune activation and CNS pathophysiology, highlighting common signaling pathways that can be targeted across domains.

Limitations and Transferability

Despite its mechanistic depth, the study is not without limitations. First, the reliance on mouse models necessitates caution in extrapolating to human TMD and depression, given potential species differences in immune–neural interactions. Second, while the work convincingly links microglial Nr4a1 and neuronal C3, the upstream triggers for their dysregulation in response to TMJ inflammation remain to be fully mapped. Further, the specificity of the NF-κB pathway in microglia versus other glial or neuronal populations was not exhaustively dissected. Nevertheless, the core signaling modules identified—Nr4a1, C3, and NF-κB—are broadly conserved and relevant to a spectrum of neuroinflammatory conditions, supporting the transferability of these mechanistic insights to related models of CNS inflammation and synaptic pathology.

Protocol Parameters

• TMJ inflammation induction: Inject complete Freund’s adjuvant (CFA) intra-articularly into the TMJ of mice; monitor for orofacial behavioral changes and inflammatory swelling 24–72 hours post-injection.
• Microglial manipulation: Use AAV vectors or transgenic mouse lines for microglia-specific overexpression or silencing of Nr4a1; confirm efficacy by qPCR and immunofluorescence.
• Microglial inhibition: Administer minocycline (e.g., 50 mg/kg, i.p.) daily starting on the day of CFA injection to suppress microglial activation.
• C3 overexpression: Deliver AAV-packaged C3 constructs to hippocampal neurons via stereotaxic injection; monitor C3 levels and synaptic markers by immunofluorescence.
• Behavioral assays: Assess depression-like behaviors using sucrose preference and forced swim tests; include open field or tail suspension as secondary endpoints.

Research Support Resources

For researchers modeling PKC/NF-κB-mediated signaling in microglial or osteoclastogenesis contexts, Verbascoside (SKU B3379) is a well-characterized small-molecule inhibitor with validated utility in both neuroinflammatory and bone metabolism assays. As reported in internal workflows, Verbascoside enables precise modulation of NF-κB activity and can be applied to cell-based models reflecting the mechanisms delineated in this study. For optimal use, prepare Verbascoside stocks in DMSO or ethanol, and store at -20°C to maintain activity. Researchers seeking to dissect the signaling events downstream of microglial Nr4a1 or neuronal C3 dysregulation may find PKC/NF-κB inhibitors such as Verbascoside valuable for protocol optimization and mechanistic validation.